$2.74
0.92% today
Nasdaq, Apr 02, 09:19 pm CET
ISIN
US57777K1060
Symbol
MXCT
Sector
Industry

MaxCyte Inc Stock price

$2.71
-0.70 20.53% 1M
-0.99 26.76% 6M
-1.45 34.86% YTD
-1.48 35.32% 1Y
-4.10 60.21% 3Y
+1.08 66.26% 5Y
+1.12 70.10% 10Y
Nasdaq, Closing price Tue, Apr 01 2025
-0.02 0.73%
ISIN
US57777K1060
Symbol
MXCT
Sector
Industry

Key metrics

Market capitalization $287.34m
Enterprise Value $150.89m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 3.91
P/S ratio (TTM) P/S ratio 7.44
P/B ratio (TTM) P/B ratio 1.39
Revenue growth (TTM) Revenue growth -6.45%
Revenue (TTM) Revenue $38.63m
EBIT (operating result TTM) EBIT $-51.06m
Free Cash Flow (TTM) Free Cash Flow $-29.26m
Cash position $154.48m
EPS (TTM) EPS $-0.39
P/E forward negative
P/S forward 6.74
EV/Sales forward 3.54
Short interest 2.83%
Show more

Is MaxCyte Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,807 stocks worldwide.

MaxCyte Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a MaxCyte Inc forecast:

7x Buy
100%

Analyst Opinions

7 Analysts have issued a MaxCyte Inc forecast:

Buy
100%

Financial data from MaxCyte Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
39 39
6% 6%
100%
- Direct Costs 11 11
29% 29%
29%
27 27
16% 16%
71%
- Selling and Administrative Expenses 52 52
2% 2%
134%
- Research and Development Expense 22 22
7% 7%
58%
-47 -47
6% 6%
-121%
- Depreciation and Amortization 4.32 4.32
4% 4%
11%
EBIT (Operating Income) EBIT -51 -51
6% 6%
-132%
Net Profit -41 -41
8% 8%
-106%

In millions USD.

Don't miss a Thing! We will send you all news about MaxCyte Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

MaxCyte Inc Stock News

Neutral
Seeking Alpha
18 days ago
MaxCyte, Inc. is rated a "Buy" due to significant upside potential despite recent share price declines. The company's core revenue is increasing and growth strategies have good prospects, driven by the strong growth of the global cell therapy market. Geopolitical tensions and a slowdown in the economy have hurt the share price, not problems in the company's business operations.
Neutral
Seeking Alpha
22 days ago
Start Time: 16:30 January 1, 0000 5:12 PM ET MaxCyte, Inc. (NASDAQ:MXCT ) Q4 2024 Earnings Conference Call March 11, 2025, 16:30 PM ET Company Participants Maher Masoud - President and CEO Doug Swirsky - CFO Erik Abdo - IR Conference Call Participants Matt Larew - William Blair Julie Simmonds - Panmure Liberum Brendan Smith - TD Cowen Mark Massaro - BTIG Matt Hewitt - Craig-Hallum Operator Than...
Neutral
GlobeNewsWire
22 days ago
ROCKVILLE, Md., March 11, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced its fourth quarter and full year ended December 31, 2024 financial results and initiated its 2025 guidance.
More MaxCyte Inc News

Company Profile

MaxCyte, Inc. engages in the development and licensing of cell-engineering technologies to pharmaceutical and biotechnology companies. Its propriety cell therapy is used in drug discovery and development, and biomanufacturing. Its products include ATx, STx, and GTx instruments. The company was founded by Douglas A. Doerfler on July 31, 1998 and is headquartered in Gaithersburg, MD.

Head office United States
CEO Maher Masoud
Employees 114
Founded 1998
Website www.maxcyte.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today